M. Hus, A. Szudy-Szczyrek, Michał Mielnik, P. Bernatowicz, J. Piszcz, A. Druzd-Sitek, Maria Czyżewska, Maciej Putowski, K. Giannopoulos
{"title":"依唑米-来那度胺-地塞米松治疗高细胞遗传学风险复发/难治性多发性骨髓瘤的有效性和安全性——波兰骨髓瘤组观察性研究的结果","authors":"M. Hus, A. Szudy-Szczyrek, Michał Mielnik, P. Bernatowicz, J. Piszcz, A. Druzd-Sitek, Maria Czyżewska, Maciej Putowski, K. Giannopoulos","doi":"10.5603/HCP.2021.0002","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":12837,"journal":{"name":"Haematologia","volume":"1 1","pages":"8-17"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effectiveness and safety of ixazomib–lenalidomide–dexamethasone in high-cytogenetic-risk relapsed/refractory multiple myeloma — results of the Polish Myeloma Group observational study\",\"authors\":\"M. Hus, A. Szudy-Szczyrek, Michał Mielnik, P. Bernatowicz, J. Piszcz, A. Druzd-Sitek, Maria Czyżewska, Maciej Putowski, K. Giannopoulos\",\"doi\":\"10.5603/HCP.2021.0002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":12837,\"journal\":{\"name\":\"Haematologia\",\"volume\":\"1 1\",\"pages\":\"8-17\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Haematologia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5603/HCP.2021.0002\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Haematologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/HCP.2021.0002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Effectiveness and safety of ixazomib–lenalidomide–dexamethasone in high-cytogenetic-risk relapsed/refractory multiple myeloma — results of the Polish Myeloma Group observational study